Cystectomy outcomes in patients who have failed Radiofrequency-induced Thermo-chemotherapeutic Effect Mitomycin-C (RITE-MMC) treatment for high-risk non-muscle invasive bladder cancer (HRNMIBC)–Does it complicate surgery and adversely impact oncological outcome?

Chemotherapeutic Effect ◽

PD19-07 ONE-YEAR FOLLOW-UP RESULTS AFTER SEQUENTIAL INTRAVESICAL BACILLUS CALMETTE-GUÉRIN AND DEVICE-ASSISTED CHEMO-HYPERTHERMIA (MITOMYCIN C DELIVERED BY THE COMBAT BRS SYSTEM) FOR HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS...A BACILLUS CALMETTE-GUÉRIN-SPARING STRATEGY

The Journal of Urology ◽

10.1016/j.juro.2017.02.880 ◽

2017 ◽

Vol 197 (4S) ◽

Cited By ~ 1

Author(s):

TR Leyshon Griffiths ◽

William JF Green ◽

Peter T Grice ◽

Jonathan C Goddard ◽

Roger C Kockelbergh

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Cancer Patients ◽

Mitomycin C ◽

Invasive Bladder Cancer ◽

Bacillus Calmette Guerin ◽

Muscle Invasive ◽

One Year

MP56-15 SEQUENTIAL BCG / ELECTROMOTIVE DRUG ADMINISTRATION (EMDA) MITOMYCIN C (MMC) AS THE STANDARD INTRAVESICAL REGIMEN IN HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER (NMIBC) – ONE YEAR OUTCOMES

The Journal of Urology ◽

10.1016/j.juro.2014.02.1583 ◽

2014 ◽

Vol 191 (4S) ◽

Author(s):

Christine Gan ◽

Suzanne Amery ◽

Kathryn Chatterton ◽

Muhammad Shamim Khan ◽

Kay Thomas ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Mitomycin C ◽

Drug Administration ◽

Invasive Bladder Cancer ◽

Muscle Invasive ◽

One Year ◽

Electromotive Drug Administration

1658 EFFICACY OF IMMEDIATE POST-TUR MITOMYCIN-C (MMC) INSTILLATION IN HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER TREATED WITH BACILLUS CALMETTE-GUERIN (BCG)

The Journal of Urology ◽

10.1016/j.juro.2011.02.1768 ◽

2011 ◽

Vol 185 (4S) ◽

Author(s):

Moon-Ki Jo ◽

Kanghyon Song ◽

Jong-Wook Park

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Mitomycin C ◽

Invasive Bladder Cancer ◽

Bacillus Calmette Guerin ◽

Intravesical sequential BCG/electromotive drug administration Mitomycin C (EMDA-MMC) in high risk non muscle invasive bladder cancer – results from a retrospective analysis

European Urology Supplements ◽

10.1016/s1569-9056(18)33383-9 ◽

2018 ◽

Vol 17 (8) ◽

pp. 357-358

Author(s):

F. Di Modugno ◽

V. Pagliarulo ◽

A. Procacci ◽

F. Bianchi ◽

S. Tafuri ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Retrospective Analysis ◽

Mitomycin C ◽

Drug Administration ◽

Invasive Bladder Cancer ◽

Muscle Invasive ◽

Electromotive Drug Administration

HIVEC HR: Chemohyperthermia with mitomycin C vs BCG for high-risk non-muscle invasive bladder cancer. Preliminary results from a randomized controlled trial

European Urology Supplements ◽

10.1016/s1569-9056(19)30563-9 ◽

2019 ◽

Vol 18 (1) ◽

pp. e768-e770 ◽

Cited By ~ 1

Author(s):

D.A. González Padilla ◽

A. González Díaz ◽

N. Miranda-Utrera ◽

F. De La Rosa Kehrmann ◽

F. Villacampa-Aubá ◽

...

Keyword(s):

Bladder Cancer ◽

Randomized Controlled Trial ◽

High Risk ◽

Mitomycin C ◽

Controlled Trial ◽

Invasive Bladder Cancer ◽

Preliminary Results ◽

Randomized Controlled ◽

The value of perioperative mitomycin C instillation in improving subsequent bacillus calmette-guerin instillation efficacy in intermediate and high-risk patients with non-muscle invasıve bladder cancer: a prospective randomized study

International braz j urol ◽

10.1590/s1677-55382012000400006 ◽

2012 ◽

Vol 38 (4) ◽

pp. 474-479 ◽

Cited By ~ 10

Author(s):

Ömer Gülpinar ◽

Ahmet H. Halilioğlu ◽

Mehmet İlker Gökçe ◽

Çagatay Göğüş ◽

Sümer Baltaci

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Mitomycin C ◽

Randomized Study ◽

Invasive Bladder Cancer ◽

Prospective Randomized Study ◽

Bacillus Calmette Guerin ◽

Risk Patients ◽

Intravesical sequential BCG/electromotive drug administration Mitomycin C (EMDA-MMC) in patients with primitive and recurrent high risk non muscle invasive bladder cancer

European Urology Supplements ◽

10.1016/s1569-9056(19)33635-8 ◽

2019 ◽

Vol 18 (9) ◽

pp. e3249

Author(s):

F. Di Modugno ◽

S. Forte ◽

V. Pagliarulo ◽

G. Lucarelli ◽

V. Pastoressa ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Mitomycin C ◽

Drug Administration ◽

Invasive Bladder Cancer ◽

Muscle Invasive ◽

Electromotive Drug Administration

Is Electromotive Mitomycin C an Alternative Treatment for Frail Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Failed Intravesical BCG?

British Journal of Medical and Surgical Urology ◽

10.1016/j.bjmsu.2009.09.003 ◽

2009 ◽

Vol 2 (6) ◽

pp. 252-252

Author(s):

B.E. Ayres ◽

B.S.I. Montgomery ◽

T. Parker ◽

J. Borwell ◽

N.J. Barber

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Mitomycin C ◽

Alternative Treatment ◽

Invasive Bladder Cancer ◽

Frail Patients ◽

Intravesical Bcg ◽

Hyperthermic mitomycin C in the treatment of high risk non muscle invasive bladder cancer – Is it effective and safe? A regional centre's experience

International Journal of Surgery ◽

10.1016/j.ijsu.2013.06.770 ◽

2013 ◽

Vol 11 (8) ◽

pp. 731 ◽

Cited By ~ 1

Author(s):

Tsong Kwong ◽

Anand Tana ◽

Ben Ayres ◽

Matthew Perry ◽

Mike Bailey ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Mitomycin C ◽

Invasive Bladder Cancer ◽

BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301)

BMC Cancer ◽

10.1186/s12885-015-1431-6 ◽

2015 ◽

Vol 15 (1) ◽

Cited By ~ 8

Author(s):

Dickon Hayne ◽

Martin Stockler ◽

Steve P. McCombie ◽

Venu Chalasani ◽

Anne Long ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Mitomycin C ◽

Phase Iii ◽

Invasive Bladder Cancer ◽

Intravesical Therapy ◽

Phase Iii Trial ◽